News stories about Oxford Immunotec Global (NASDAQ:OXFD) have been trending somewhat positive recently, according to Accern Sentiment. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Oxford Immunotec Global earned a coverage optimism score of 0.22 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 45.0712075539075 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Shares of Oxford Immunotec Global (NASDAQ OXFD) opened at $11.87 on Tuesday. Oxford Immunotec Global has a 1 year low of $10.81 and a 1 year high of $19.51. The company has a market cap of $295.29, a PE ratio of -5.88 and a beta of -0.09. The company has a debt-to-equity ratio of 0.38, a quick ratio of 4.30 and a current ratio of 4.72.

Oxford Immunotec Global (NASDAQ:OXFD) last announced its quarterly earnings results on Tuesday, October 31st. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.02. Oxford Immunotec Global had a negative net margin of 45.74% and a negative return on equity of 38.42%. equities analysts predict that Oxford Immunotec Global will post -2.16 earnings per share for the current fiscal year.

Several analysts recently commented on the stock. Piper Jaffray Companies cut their price objective on shares of Oxford Immunotec Global from $26.00 to $19.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 31st. BTIG Research set a $21.00 price objective on shares of Oxford Immunotec Global and gave the company a “buy” rating in a research report on Monday, December 18th. Robert W. Baird reissued a “buy” rating and set a $20.00 price objective on shares of Oxford Immunotec Global in a research report on Wednesday, November 1st. BidaskClub raised shares of Oxford Immunotec Global from a “sell” rating to a “hold” rating in a research report on Friday, December 15th. Finally, Cowen reissued a “buy” rating and set a $15.00 price objective on shares of Oxford Immunotec Global in a research report on Monday. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $18.75.

In other news, Director Richard A. Sandberg sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $13.35, for a total transaction of $40,050.00. Following the sale, the director now owns 17,778 shares of the company’s stock, valued at approximately $237,336.30. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 8.11% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Oxford Immunotec Global (OXFD) Receives Daily Media Impact Score of 0.22” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at

About Oxford Immunotec Global

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Insider Buying and Selling by Quarter for Oxford Immunotec Global (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with's FREE daily email newsletter.